ArticleCureus2024
Neuroregenerative Effects of Radio Electric Asymmetric Conveyer (REAC) Neuroregenerative (RGN-N) Therapy in Pediatric Adrenoleukodystrophy: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Reversal of Endogenous Bioelectrical Network Collapse in Advanced Childhood Cerebral X-Linked Adrenoleukodystrophy.Neurology international · 2026Article
- REAC RGN-AR treatment modulates adipogenic differentiation in adipose tissue-derived stem cells.Scientific reports · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report presents the use of radio electric asymmetric conveyer (REAC) neuroregenerative (RGN-N) therapy in a pediatric patient with adrenoleukodystrophy (ALD), a progressive neurodegenerative disorder with limited therapeutic options. The patient underwent three REAC RGN-N treatment cycles, each lasting 72 hours, with approximately 6-7 hours of daily sessions. An asymmetric conveyor probe (ACP) was positioned along the spine to channel the interaction of the emitted radio electric field with cellular electro-metabolic alterations, promoting progressive bioelectrical restoration. The treatment parameters were pre-set on the REAC device (BENE 110, ASMED, Scandicci, Italy) and could not be altered by the operator, ensuring consistent therapeutic delivery. Significant functional improvements were observed across the motor, cognitive, and swallowing domains, as assessed by standardized scales. This report aligns with preclinical studies on REAC technology's potential for neuroregeneration and suggests REAC RGN-N therapy as a promising adjunctive intervention in ALD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.